STOCK TITAN

Cellyan Biotechnology regains Nasdaq bid compliance

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Cellyan Biotechnology Co., Ltd (HKPD) regained compliance with Nasdaq’s US$1.00 per-share minimum bid price requirement for continued listing on the Nasdaq Capital Market. Nasdaq notified the company on November 13, 2026, that the matter was closed after its Class A ordinary shares had a closing bid price of at least US$1.00 for 14 consecutive business days, from October 26 through November 12, 2026.

Nasdaq had notified Cellyan in January 2026 that its shares were below US$1.00 for 30 consecutive business days. Nasdaq provided an initial 180-calendar-day compliance period through July 13, 2026, then granted an additional 180 calendar days on July 14, through January 11, 2027. The 14-day price streak satisfied the requirement, and Nasdaq closed the matter.

Minimum bid price US$1.00 per share Nasdaq minimum bid price requirement for continued listing
Qualifying price streak 14 consecutive business days October 26 through November 12, 2026
Required price streak 10 consecutive business days Minimum period required during the compliance period
Below-threshold period 30 consecutive business days Closing bid price was below US$1.00 per share
Initial compliance period 180 calendar days Through July 13, 2026
Additional compliance period 180 calendar days Granted July 14, 2026, through January 11, 2027
Minimum Bid Price Requirement regulatory
"regained compliance with the Minimum Bid Price Requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"under Nasdaq Listing Rule 5550(a)(2)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did HKPD regain Nasdaq minimum bid-price compliance?

Yes. Nasdaq notified Cellyan on November 13, 2026, that it had regained compliance with the US$1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market, and that the matter was closed.

How many days did HKPD meet Nasdaq’s minimum bid-price requirement?

Nasdaq determined that Cellyan’s Class A ordinary shares had a closing bid price of at least US$1.00 per share for 14 consecutive business days, from October 26 through November 12, 2026. The stated compliance standard required at least 10 consecutive business days during the compliance period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number 001-42468

 

CELLYAN BIOTECHNOLOGY CO., LTD

(Exact name of registrant as specified in its charter)

 

Cayman Islands

(Jurisdiction of incorporation or organization)

 

4/ Room B1, 5/F., Well Town Industrial Building,

13 Ko Fai Road, Yau Tong, Kowloon

Hong Kong

 

 

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant file or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F ☐ 

 

 

 

 

 

 

On November 13, 2026, Cellyan Biotechnology Co., Ltd (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) stating that because the Company’s Class A ordinary shares had a closing bid price at or above $1.00 per share for the last 14 consecutive business days, from October 26 through November 12, 2026, the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2), and that the matter is now closed.

 

EXHIBIT INDEX

 

Exhibits

 

Exhibit No.   Description
99.1   Press Release

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on November 16, 2026.

 

  CELLYAN BIOTECHNOLOGY CO., LTD
     
  By: /s/ Chenyu Liang
  Name:  Chenyu Liang
  Title: Director and Chief Executive Officer

 

2

 

Exhibit 99.1

 

CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

 

Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on the Nasdaq Capital Market.

 

As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company’s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, as a result, the Company was not in compliance with the Minimum Bid Price Requirement. Nasdaq provided the Company with an initial compliance period of 180 calendar days, or until July 13, 2026, to regain compliance. To regain compliance, the Company was required to maintain a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days during the compliance period. On July 14, 2026, the Company received written notice from Nasdaq granting an additional 180 calendar days, or until January 11, 2027, to regain compliance with the Minimum Bid Price Requirement.

 

Subsequently, on November 13, 2026, Nasdaq determined that the closing bid price of the Company’s Class A ordinary shares was at least US$1.00 per share for the 14 consecutive business days from October 26 through November 12, 2026. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirement, and the matter was closed.

 

About Cellyan Biotechnology Co., Ltd

 

Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited) offers two main categories of services: (i) OTC pharmaceutical cross-border e-commerce supply chain services through its Hong Kong subsidiary, Joint Cross Border Logistics Company Limited (“Joint Cross Border”), and (ii) OTC pharmaceutical cross-border procurement and distribution through its Hong Kong subsidiary, V-Alliance Technology Supplies Limited.

 

Through its engagement with OTC pharmaceutical suppliers, logistics companies, and merchants on Chinese e-commerce platforms, Joint Cross Border provides a convenient one-stop solution for Mainland Chinese customers seeking access to OTC pharmaceutical products outside Mainland China. Joint Cross Border’s comprehensive service offerings include pre-consultation, product information review, procuring overseas OTC pharmaceutical products, enlisting products with the Hong Kong Department of Health, obtaining import and export permits, storing products, packaging, and arranging logistics and end-to-end delivery services for customers.

 

For investor and media inquiries please contact: 

 

Cellyan Biotechnology Co., Ltd

Media Contact: andy@cell-yan.com 

Investor Relations: stella@cell-yan.com

 

Filing Exhibits & Attachments

1 document

Keep reading